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Abstract 
 
When a clinical trial is subject to a series of interim analyses as a result of which the study 
may be terminated or modified, final frequentist analyses need to take account of the 
design used.  Failure to do so may result in overstated levels of significance, biased effect 
estimates and confidence intervals with inadequate coverage probabilities.  A wide variety 
of valid methods of frequentist analysis have been devised for sequential designs comparing 
a single experimental treatment with a single control treatment.  It is less clear how to 
perform the final analysis of a sequential or adaptive design applied in a more complex 
setting, for example to determine which treatment or set of treatments amongst several 
candidates should be recommended.   
This paper has been motivated by consideration of a trial in which four treatments 
for sepsis are to be compared, with interim analyses allowing the dropping of treatments or 
termination of the trial to declare a single winner or to conclude that there is little 
difference between the treatments that remain.  The approach taken is based on the 
method of Rao-Blackwellisation which enhances the accuracy of unbiased estimates 
available from the first interim analysis by taking their conditional expectations given final 
sufficient statistics.  Analytic approaches to determine such expectations are difficult and 
specific to the details of the design, and instead “reverse simulations” are conducted to 
construct replicate realisations of the first interim analysis from the final test statistics.  The 
method also provides approximate confidence intervals for the differences between 
treatments. 
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1. Introduction 
 
This paper is motivated by a design for a trial in sepsis [1], with the objective of comparing 
four treatments for sepsis in respect of survival of the patient to 28 days, analysed as a 
binary response and referred to as “success”.  Although one of the treatments is standard 
care, it is given no special privileges: all four treatments are dealt with in the same way.  At 
each of a series of interim analyses, all pairwise comparisons of remaining treatments are 
made.  Any treatment that is worse than any other according to pre-determined criteria is 
eliminated from the trial.  If only one treatment remains, it is declared the winner and the 
trial stops.  If all remaining treatments are sufficiently similar to one another, they are 
declared joint winners and the trial stops.  Otherwise the trial continues to the next interim 
analysis.  At the end of such a trial, how should the differences between the performances 
of the treatments be estimated, bearing in mind the potential biases introduced by the 
elimination and stopping rules [2]? 
 Estimation following a sequential trial has a rich statistical literature.  For the case of 
trials comparing two treatments, methods may be based on orderings of the final sample 
space [3-6] or on direct adjustment of the maximum likelihood estimate to reduce its bias 
[7].  Overviews of alternative approaches are available [8, 9].  For adaptive designs, which 
are not entirely pre-defined, estimation methods can be devised by extending the ordering 
approach [10, 11] or through shrinkage approaches [12, 13].  In this paper, an approach 
based on Rao-Blackwellisation [14, 15] will be developed.  This is a method that has been 
adopted by previous authors for certain specific designs [16, 17]. 
 It is difficult to generalise approaches based on orderings of the final sample space 
to trials of multiple treatments because there are so many possible final samples and it 
becomes unclear how to determine which provide stronger evidence favouring a given 
alternative over the null than the sample observed.  Direct adjustment of maximum 
likelihood estimates depends on knowledge of the distribution of the final sample statistics 
around the stopping boundary.  While this can be characterised for a comparison of two 
treatments that relies on a single test statistic, it is far more challenging to achieve for 
multiple treatments compared in respect of several pairwise test statistics.  Here the Rao-
Blackwellisation approach will be developed.  This is based on the expected value of an 
unbiased estimate computed at the first interim analysis (and thus unaffected by any 
stopping rules), conditional on sufficient statistics computed at the end of the study.  Rather 
than finding this test statistic and its standard error analytically, it will be determined by 
reverse simulation.  That is, starting with the final values of the numbers of patients and the 
numbers of successes for each treatment (and when present, within each stratum), 
hypergeometric sampling will be used to create possible samples at each earlier interim 
analysis until that at the first interim has been recreated.  Only those sequences that are 
consistent with continuation to the observed end of the sequential procedure are accepted.  
The mean and variance of unbiased estimates from each acceptable replicate simulated first 
interim analysis are then used to provide unbiased estimates and approximate confidence 
intervals that allow for the sequential nature of the design. 
 The approach developed has the potential for implementation following a wide 
range of multiple treatment trials and flexible adaptive designs.  It is often easier to work 
backwards from the end of the trial and determine which sequences of data would have led 
to continuation to the final sample, than to project such sequences from the outset.  Much 
of the development and evaluation of the method will be made in the context of a 
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conventional sequential comparison of just two treatments because that setting is simpler 
analytically and computationally, and because it allows comparisons to be made with more 
established methods. 
 In the next section the trial design described in [1] is reviewed.  Instead of using the 
elimination and stopping rules proposed in that paper, the performance of alternative rules 
based on the triangular test [8] is examined.  It must be emphasised that this design serves 
here only as an illustration of the new estimation approach.   The latter could be applied to 
a wide range of multiple treatment designs and indeed other forms of flexible adaptive 
design.  In Section 3, the simple comparative triangular design that forms the basis of the 
four treatment evaluation is extracted and examined in isolation, and in Section 4, naïve and 
orderings-based analyses are developed in the two-treatment context, together with two 
forms of the Rao-Blackwellisation approach.  The new method is applied to simulated data 
from the four treatment design in Section 5, and Section 6 draws together conclusions from 
this work. 
 
 
2. A design for the comparison of four treatments 
 
The design introduced by Magaret et el. [1] comprised up to four successive analyses based 
on constant nominal -levels.  Here the overall structure of that design is retained but a 
different approach is taken to the elimination and stopping rules: one which will allow the 
extraction of a simple triangular test [8] for examination in the central sections of this 
paper.   
 Treatment effects are expressed in terms of odds ratios for success.  The value 1.5 is 
taken to be of clinical importance.  The probability of success (survival to 28 days) for a 
patient receiving treatment Ti is denoted by pi, i = 1, ..., 4.  The log-odds ratio for treatment 
Ti relative to Tj is denoted by ij = log[{pi(1 – pj)}/{pj(1 – pi)}].  The design seeks to satisfy the 
following requirements.  Type I error requirement:   For any treatment Ti, if there is another 
treatment Tj, i  j such that pi = pj, then the probability that the trial finds Ti to be the sole 
winner is to be  0.025.  Power requirement:   For any pair of treatments Ti and Tj, if Ti is 
superior to Tj to the extent that ij = log(1.5), then the probability that Tj would be 
eliminated from the study is to be  0.90.   
 Interim analyses occur whenever 36 new patient outcomes become available on 
each of the treatments remaining in the study.  The maximum sample size is set at 2772 
patient responses and interim analyses continue until the trial stopping rules are satisfied or 
else it is impossible to assign 36 more patients to all remaining treatments within this quota.  
The probability that not all treatment comparisons will be resolved after 2772 patient 
responses have been observed is small.  If all four treatments were to remain in the trial, the 
maximum number of interim analyses would be about 20: more could occur if treatments 
were eliminated.   
 At the kth interim analysis, every pair of treatments Ti and Tj will be compared in 
terms of the statistics Zijk and Vijk where  
 
jk ik ik jk
ijk
ik jk
n S n S
Z
n n



       and     
  
 
ik jk ik jk ik jk ik jk
ijk 3
ik jk
n n S S n n S S
V
n n
   


.                          (1) 
 
4 
 
Here nik denotes the number of patient responses available for patients on Treatment T i, 
and Sik the number of those who have survived to Day 28.  For a stratified version of the 
procedure, the statistics shown are computed separately within each stratum, and then 
summed over strata to provide the values of Zijk and Vijk to be used.   
 At the kth interim analysis, it is concluded that Ti is better than Tj if Zijk ≥ 10.90266 + 
0.12380Vijk, no different from Tj if Zijk  (10.90266  0.37140Vijk, 10.90266 + 0.37140Vijk), 
and worse than Tj if Zijk ≤ 10.90266  0.12380Vijk.  If the interval used to judge no 
difference is empty because the left-hand limit is larger than the right-hand limit, then the 
no difference conclusion is not possible.   Whenever one treatment is found to be worse 
than another according to this criterion, that treatment is eliminated from the trial.  
Randomisation continues between the remaining treatments, and interim analyses continue 
to take place whenever 36 new outcomes have become available for each remaining 
treatment.  The trial stops when only one treatment remains, or when all remaining 
treatments are found to be no different from one another.  For the purposes of the 
simulations conducted here, the trial also stops if a further interim analysis would require 
the total number of patients to exceed 2772, although in practice investigators might 
choose an alternative strategy as discussed later in this section. 
 The elimination and stopping rules, as they relate to a comparison between one pair 
of treatments, are shown in Figure 1.  Each interim analysis is represented by a disc on the 
boundaries, and at the kth interim analysis, the value of Zijk is plotted against that of Vijk, and 
the conclusion indicated is drawn.  The design has been developed from a double triangular 
design devised to compare two experimental treatments [8, 18].  The boundaries are 
computed to satisfy the type I error and power requirements mentioned above, interpreted 
for the simple case of two treatments.  Computation is based on the SEQ function of SAS, 
following [19, 20], but using the four boundary option of SEQ.  The increment in information 
between interim analyses for this double triangular test is V = 4.40337.  When p1 = 0.40 and 
p2 = 0.50 or when p1 = 0.50 and p2 = 0.60 (both corresponding to an odds ratio of 1.5), this 
corresponds to an increase in sample size between interim analyses of 35.58 per treatment, 
which is rounded up to 36 in this application.   
 Applied to the case of four treatments, the type I error and power requirements 
specified at the beginning of this section are valid.  The probability that T1 is declared the 
sole winner, when in fact p1 = p2 is greatest when the success rates on T3 and T4 are both 
zero so that there is no chance of them being declared either sole or joint winners.  There 
would also be a negligible chance that they would be declared no different from T1 or from 
T2 or from both.   In this circumstance, the probability that T1 would be declared the sole 
winner is therefore equal to the probability of T1 being found better than T2 in the double 
triangular test when 12 = 0: that is 0.025.  Furthermore, the probability that T1 is 
eliminated, when 12 = log(1.5) is least when the success rates on T3 and T4 are both zero so 
that there is no chance that T1 would be eliminated relative to them.  In this circumstance, 
the probability that T1 would be eliminated is therefore equal to the probability of T2 being 
found better than T1 in the double triangular test when 12 = log(1.5): that is 0.900.   
 Properties of the design estimated from million-fold simulations, are shown in Table 
1 below.  In each of the Cases 1-12, one set of treatments share a high success rate and the 
rest share a low rate, with the odds ratio between the two rates being 1.5.  In Cases 13-16, 
all success rates are equal.  Also shown are “Mixed Cases”.  For these, we imagine that the 
trial is conducted at four centres each recruiting equal numbers of patients.  In the 
simulations, the 36 patients recruited to each treatment for each new interim analysis are 
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distributed amongst the centres at random.  The four centres in the mixed cases each have 
a different set of success probabilities, namely the four sets shown in the cases above.  In 
the simulations for the mixed cases, the statistics Z and V given in (1) are stratified for 
centre: that is the four within-centre values of Z and V are calculated and then summed to 
provide the values to be compared with the stopping boundaries.   
 In Cases 1-4 and Mixed Case I, the probability that T4 is correctly eliminated exceeds 
0.90, as specified in the power requirement.  This is true for T2 and T3 as well, although 
these results are not shown: in general the full results reflect the symmetry of each 
scenario.  Treatment T1 is correctly selected with a probability exceeding 0.80: this is a 
desirable feature, although not part of the formal specification.  In Cases 5-8 and Mixed 
Case II, the probability of wrongly declaring T1 to be the winner is no more than 0.026, 
(essentially) satisfying the type I error requirement.  The probability of eliminating T4 is well 
above the value of 0.90 of the power requirement.  The probability of correctly declaring T1 
and T2 to be joint winners is above 0.90, except for Case 8 where it is 0.885.    In Cases 9-12 
and Mixed Case III, the probability that T1 wins is 0.005 and the probability that T4 is 
eliminated is greater than 0.975.  The probability of correctly identifying the three joint 
winners is greater than 0.814.  Finally, in Cases 13-16 and Mixed Case IV, the probability that 
T1 wins is 0.002 or less in all cases.  The probability of correctly identifying all four 
treatments as no different is greater than 0.748, except for case 16 where it is 0.591.     
 Average total sample sizes at termination are around 1400-2400.  Sample sizes are 
smaller when success probabilities are close to ½, and larger when they are close to 1 or to 
0.  They are also smaller when there is a single treatment that is more efficacious than the 
others, or when there are two good treatments.  Cases where three or all four treatments 
are equally efficacious require larger sample sizes before a conclusion is reached.  Ethically, 
this is sound, as if all treatments are the same, no group of patients is being disadvantaged 
by being in the trial.  By the same token, patients not in the trial are under no disadvantage 
due to the length of the trial.  The full results show that sample sizes on poor treatments 
tend to be small, those on good treatments to be large, indicating the effectiveness of 
eliminating poor treatments.  The percentage of inconclusive trials was 26.6% in Case 16.  In 
all other cases, such percentages are small or negligible.  If the trial ends without identifying 
a single winner or concluding that there is no difference between the remaining treatments, 
then investigators can accept the result available, or else recruit additional patients to force 
a conclusion. 
 The construction of the decision rules of the design guarantees that it is not possible 
to declare two treatments to be no different from one another during the first 6 interim 
analyses (see Figure 1).  It is possible to stop at any analysis to conclude that one of the 
treatments is better than all of the others, but the evidence has to be very clear.  Minimal 
evidence for T2 to be eliminated relative to T1 at the first interim analysis requires 23 
successes out of 36 on T1 and none on T2: the corresponding one-sided nominal p lies well 
below 0.00001.   In fact, under most realistic scenarios, the probability of stopping at one of 
first three interim analyses is negligible.   
 It can be seen that the procedure presented here achieves the type I error and 
power requirements specified, and has other desirable properties in terms of high 
probabilities of appropriate conclusions and relatively low expected sample sizes.   It must 
be stressed that these interim analyses are very simple to carry out.  The following 
information on all patients randomised 28 days ago or earlier is all that is needed: Patient 
identification number; Treatment centre and any other baseline stratification factors; Date 
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of randomisation; Treatment arm (T1, T2, T3 or T4); and Survived to Day 28 (YES or NO).  All 
but the last are available for a month before the patient is to be included in interim 
analyses.  More extensive reviews of the data might be planned, perhaps to coincide with 
every 4th or every 5th interim analysis.  Interim analyses are to be conducted whenever the 
average number of patient responses per remaining treatment collected since the previous 
interim analysis reaches 36.  Ideally, this should be 36 patients per treatment, but the 
formulae given at (1) can be used when sample sizes are unequal, and the accuracy will 
remain good provided that sample sizes per treatment are approximately equal.  The 
method is also likely to be forgiving of slight slippage from an average of exactly 36 new 
patients per treatment. 
 
 
3. Conventional post-trial estimation for a simple triangular test 
 
Now consider a comparison between just two treatments, T1 and T2.  A series of up to 20 
interim analyses are conducted, at the kth of which the statistics Z12k and V12k defined in (1) 
will be computed.  Here, they will be denoted simply as Zk and Vk, and the log-odds ratio 12 
by .   The trial will be stopped with the conclusion that T1 is better than T2 if Zk ≥ 10.93898 + 
0.123134Vk, or with the conclusion that T1 is no better than T2 if Zk  10.93898 + 
0.369402Vk.   The design is constructed using published code [19, 20], and the risk of one-
sided type I error is set to 0.025 and the power for an odds ratio of 1.5 to 0.90.  Note that 
the boundaries differ slightly from those used in the four treatment case, because the latter 
were based on the properties of pairwise double triangular tests.  Here, T1 can be thought of 
as the experimental treatment and T2 as the control: the design is asymmetric in dealing 
with the treatments.  The maximum value of V is V20 = 88.8380, at which point the stopping 
boundaries meet.  Hence V1 = 4.4419.  For p1 = 0.60 and p2 = 0.50, so that  = log(1.5), the 
total sample size per interim analysis is approximately 72 (36 per treatment).  In simulations 
reported here, additional interim analyses are conducted beyond the 20 initially planned, up 
to a maximum of 25, if increments in V fall short of the anticipated value of 4.4419 and no 
boundary has been reached.  In practice, if increments in V are observed to be low, then 
sample sizes per interim can be increased.  
 Table 2 shows the results of 12 simulated realisations of this triangular design, 
ordered by increasing strength of evidence that T1 is better than T2.  Also given are results of 
a naïve analysis in which the sequential nature of the design is ignored, and a valid analysis 
based on the ordering of Fairbanks and Madsen [21].  For the naïve analysis, the estimated 
value of  is taken to be ˆ  = Z*/V* with standard error se = 1/V*, and the corresponding 
95% confidence interval (L, U) is ( ˆ   1.96se), where Z* and V* are the values of Z and V 
found from the final dataset.  The orderings analysis is computed following [19] and [20].  In 
each computation the value of Vi is taken to be equal to i*V20/20.  In practice the true values 
of the Vi would be used, but the approximation is used here for simplicity, and to allow 
readers to check the computation of the estimates.  The analysis methods developed in the 
next section do not depend on the intermediate values of the Vi.  The bias-adjusted 
estimate [7] has no corresponding accurate method for computing confidence intervals and 
for that reason, it is not explored here.  
The orderings analysis provides valid p-values and reduces estimates of  when the 
upper boundary is crossed and increases them in the case of the lower boundary.  It 
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provides totally satisfactory results based on the actual sequential design used.  However, it 
is difficult to see how it might be generalised for use following a sequential comparison of 
more than two treatments. 
 
 
4. Post-trial estimation based on Rao-Blackwellisation for a simple triangular test 
 
The Rao-Blackwellisation approach [14, 15] is based on the estimate 1 1 1
ˆ Z / V   deduced 
from the data available at the first interim analysis, which is unbiased for  as it does not 
depend on the stopping rule in any way.  Consequently, the estimate  1ˆE Z ,V   , is also 
unbiased for  and has smaller variance.  The estimate is truncation-adaptable, meaning 
that it depends only on the form of the interim analyses that were performed and not on 
those that were planned to take place but did not.  Orderings analyses are also truncation-
adaptable, but the bias adjusted method [7] is not.  The estimator   achieves minimum 
variance within the class of unbiased truncation-adaptable estimators [22]. 
 Now  E   , and  
 
              1 1 1 1 1ˆ ˆ ˆ ˆvar var E Z ,V var E var Z ,V 1 V E var Z ,V .               
 
In order to compute confidence intervals, it will be assumed that the pivot 
    E var    follows the standard normal distribution and that   1ˆE var Z ,V   
can be reliably estimated by  1ˆvar Z ,V  .  Thus the standard error of   is given by 
 
      1 1ˆse 1 V var Z ,V      ,                                                                       (2) 
 
and an approximate 95% confidence interval for  is   1.96se  .  It is unlikely that 
either of the assumptions on which this approach is based are more than approximately 
true.  The accuracy of the derived confidence intervals should be evaluated by simulation 
for any given application.  The theoretical basis for the unbiasedness of the estimate   is far 
stronger than that for the accuracy of the confidence interval. 
Two methods for evaluating   and  se   will now be developed.  The first, Method 
RB1, is an analytical approach depending on known properties of the triangular test.  It is 
infeasible to generalise RB1 to the four treatment case, and it is included here for 
comparison and checking.  Method RB2 employs reverse simulation to re-create replicate 
observations of Z1 and V1, and is applicable in complicated situations such as a comparison 
of four treatments.   
 
4.1 Method RB1 
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Denote the lower and upper stopping limits for Zk at the k
th interim analysis by k and uk 
respectively, k = 1, 2, ... .  The sequential design based on the first n of these interim 
analyses, which is then truncated, is denoted by Rn.  The interim analysis at which the design 
Rn actually stops will be denoted by K[n], and the corresponding final values of the test 
statistics by Z[n] and V[n].  Equation (5.38) of [8] defines the function f[n](z, k, ) to be 
 
       z 0 [n] [n]n
1
f z,k, lim P Z z,z z ,K k
z
     

,   k = 1, ..., n.                                        (3) 
 
The sequence of functions f[i](z, k, ) for z < k or z > uk, k = 1, ..., n – 1, and f[n](z, n, ), 
together provide a density for the final position of the test statistics (Z[n], V[n]) over all of 
their possible final values.  Using Equation (5.41) of [8], it can be shown that for any 
         
2
n n n nn n
f z ,n, exp z V f z ,n,0   , as pointed out in [15]. 
 Now, let 
 
        
nz
nn n
F z ,n, f s,n, ds

   . 
 
This is the probability that the design Rn stops at the n
th interim analysis with Z[n] ≤ zn.  In 
fact, it is the probability that any design which shares with Rn the stopping limits for its first 
n interim analyses stops at the nth interim analysis with Z[n] ≤ zn.  This function can be 
evaluated using the SAS function SEQ.  Note that  
 
   nnF z ,n,       
2
n n nn
exp z V F z ,n,0 .                                                                           (4) 
 
The probability that the design Rn stops at the n
th interim analysis with Z[n]  (zn – z, zn + z)  
is given by        n nn nF z z,n, F z z,n,     . 
 Next, consider the adjusted sequential test, in which the first lower limit is amended 
to be 1 + t, t  (0, u1 – ).  The functions corresponding to f[n] and F[n] for this design will be 
denoted by  
 t
n
f  and  
 t
n
F  respectively.  Then, the probability that the sequential design Rn 
starts with a value of z1 lying above 1 + t and then later stops at the n
th interim analysis with 
Z[n]  (zn – z, zn + z) is given by  
     
   t tn nn nF z z,n, F z z,n,     .  Denote the conditional 
probability that Z1 lies above 1 + t, given that the trial stops at the n
th interim analysis with 
Z[n]  (zn – z, zn + z) by S(t; ).  Then         1 1 n nn nS t; P Z t K n,Z z z,z z        .   It 
follows, using (4), that 
 
    
     
   
       
t t
n nn n
n nn n
F z z,n,0 F z z,n,0
S t
F z z,n,0 F z z,n,0
  

  
,                                                                           (5) 
 
where the value of  is suppressed in the notation for S.  This confirms the sufficiency of the 
statistics Z[n] and J[n].  It can be shown that 
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    1 1
u
1 1 [n] [n]0
S t dt E Z K ,Z

    and      
1 1u 2
1 1 [n] [n]0
2 tS t dt E Z K ,Z .

             (6)   
              
Suppose that a trial with stopping limits at the first n interim analyses of (1, u1), ... , (n, un) 
stops with Zn = zn.  Thus K[n] = n and Z[n] = zn.  The value of        n nn nF z z,n,0 F z z,n,0    
can be evaluated using the SAS function SEQ for the trial stopping limits with the 
modification that the nth continuation region is (zn – z, zn + z).  The value of z is chosen to 
be small, but large enough for the resulting nth continuation probability to be reported with 
a reasonable number of decimal places.  Then  
     
   t tn nn nF z z,n,0 F z z,n,0    is evaluated 
in a similar way, but for a design with first continuation region given by (1 + t, u1) for a grid 
of values of t between 0 and u1  1.   This allows S(t) to be found from (5) for the same grid 
of values, from which the conditional mean and standard deviation of Z1 given K[n] = n and 
Z[n] = zn can be found from (6) using numerical integration.  Note that the function SEQ is 
constructed for stopping limits for Zn/V1.  This necessitates some intricate programming in 
order to obtain the correct answers. 
 
4.2 Method RB2 
For reverse simulation, the estimate  1ˆE ,   S n  is used, where S* and n* are the 
vectors of numbers of successes and numbers of patients, by treatment, in the final dataset.  
The final interim analysis will be taken to be the Kth.  The number of successes on Ti at the 
kth interim analysis, Sik, is simulated as a hypergeometric observation, being the number of 
successes in a draw of nik patient responses from a total of ni,k+1 responses of which Si,k+1 are 
successes, i = 1, 2; k = K – 1, K – 2, ..., 1.  For each replicate simulation, the estimate 
1 1 1
ˆ Z V   is found from (1) using the simulated numbers of successes on the two 
treatments at the first interim analysis.  All values of Zk and Vk, k = 1, ..., K – 1, are checked, 
and any simulated sample path that corresponds to a trial that would have stopped 
according to the sequential design is deleted from the set of simulated runs.  Then the mean 
and variance of the remaining values of 1ˆ are used as   and  1ˆvar ,  S n  respectively.  
The latter is used in place of  1ˆvar Z ,V  in (2) to provide a value for  se  .  The set of 
simulated realisations of the first interim analysis can be used in a similar way to provide 
unbiased estimates of the success probabilities p1 and p2, allowing for the sequential nature 
of the trial. 
 
4.3 Evaluation of Methods RB1 and RB2 
Table 3 presents results from analyses of the 12 cases presented in Table 2 using Rao-
Blackwellisation methods.  For Method RB1, the value of z in (5) was set at 0.01, and a grid 
of 100 points was used to evaluate the integrals in (6).  For Method RB2, 10 million-fold 
reverse simulations were generated, and the first column in the RB2 section of the table 
shows that between 17.0% and 99.3% of the replicates were complete: that is they 
corresponded to sequential trials that would not have stopped prior to the observed final 
interim analysis.  Figure 2 shows the estimate and confidence intervals from the Rao-
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Blackwellisation approaches and the same quantities from the naïve and orderings analysis, 
plotted against the values of the naïve estimates.  The value of the naïve estimate is 
subtracted from all quantities, in order to provide a clearer view of the differences between 
the methods.  The 12 cases are ordered with respect to the naïve estimates, and so Cases 1 
to 12 are the points indicated by crosses running from left to right.  The vertical line at  = 
0.2462 represents the value of treatment effect at which the trend of the plot of Z against V 
would head for the tip of the triangle, for this is the average of the boundary slopes.   
When the naïve estimate lies below 0.2462, both adjustments increase the 
magnitude of the estimate, with those due to the Rao-Blackwell estimate being greater.  
When the naïve estimate lies above 0.2462, both adjustments reduce the magnitude of the 
estimate, with those due to the Rao-Blackwell estimate again being greater.  Adjustments 
using Method RB1 are a little more extreme than those using RB2.   
The naïve confidence limits are narrowest and will fail to meet the target coverage 
probability.  The Method RB1 leads to the widest intervals, followed closely by RB2.  When 
the naïve estimate lies below 0.2462, adjusted limits lie above the corresponding naïve 
limits and when it lies below 0.2462 they lie below.  This effect is greatest for the Rao-
Blackwell approaches.  In cases in which there is a large overshoot of the boundary at the 
final interim analysis (Cases 6, 8, 9 and 11), the adjustments for sequential analysis have the 
greatest effect on the estimate of .  In cases where the overshoot is small (Cases 5, 10 and 
12), the adjustments for sequential analysis have less effect on the estimate of .  The SAS 
programs leading to the RB1 and RB2 analyses shown in Table 3 are provided as 
supplementary material of this paper. 
 Table 4 presents the results of 1000-fold simulations of the naïve approach and of 
Methods RB1 and RB2 for three true values of .  These are the null value, 0; the alternative 
value log(1.5) = 0.405; and between these the value 0.246 which is the average of the two 
boundary slopes.  In each case the control success probability was set at pC = 0.6. The results 
from the naïve approach confirm that there is a problem to be addressed.  In particular, 
when  = 0.405 the effect of the treatment is systematically overestimated, and in all three 
cases the coverage probability of confidence intervals is inadequate.  For Method RB1, the 
grid is again constructed of 100 points and the value of z set as 0.01.  For Method RB2, for 
reasons of computing time, one million replicate reverse simulations were used rather than 
the ten million that underlay the results presented in Table 3.  The Rao-Blackwellised 
estimate   is presented with its standard deviation computed from the 1000 replicate 
values and its standard error, which is the mean of the values computed from (2).  These 
two values are close to one another, in support of the basis of computation.  For both 
methods, the bias of   is small.  The coverage probabilities of the 95% confidence intervals 
are around 0.970 (and significantly greater than 0.95 at the one-sided 2.5% level) in each 
case.  They could therefore be used in practice as conservative computations.   
  
 
5. Application to the comparison of four treatments 
 
A single set of simulated data consistent with the design proposed in Section 1 is used to 
illustrate the implementation of Rao-Blackwellisation in a more complicated situation.  
Table 5 displays the data from this single realisation.  This summary is sufficient for analysis 
according to Method RB2.  There are six pairwise treatment comparisons to consider.  Table 
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6 presents the final values of the test statistics Z and V for each of these comparisons.  
Treatment T2 was eliminated in comparison with T1 at the 4
th interim analysis, and T4 
followed at the 5th.  This left T1 and T3, which continued to be monitored until the 12
th 
interim analysis, at which point T1 was found to be the winner. 
 Whether the analysis is conducted allowing for the sequential design used or not, 
two options are available for the final analysis.  Option 1 is to use all data available on each 
treatment in making each comparison.  Option 2 is to restrict the data used in any pairwise 
comparison to that collected from patients randomised when both treatments were still in 
contention.  This is the form of analysis reflected in the values of Z and V displayed in Table 
6.  It avoids biases that may be caused by any temporal effects on the nature of the patients 
recruited, on the manner in which treatments were administered, or on how observations 
were recorded.  Option 2 will be adopted here. 
 To implement Option 2, three separate reverse simulations have to be performed.  
To compute the estimate 13  and its standard error, reverse simulation is conducted from 
the 12th interim analysis, at which T1 was found to be better than T3, leading to the 
termination of the whole trial.  From Table 5, it can be seen that at the 12th interim analysis 
at Centre 1, T1 had been administered to 103 patients with 83 successes and T3 to 111 
patients with 85 successes.  At the 11th interim analysis at Centre 1, T1 had been 
administered to 98 patients and T3 to 102 patients.  For the reverse simulation, the number 
of successes on T1 at Centre 1 is generated as a hypergeometric random variable: the 
number of successes from 98 patients drawn randomly from 103 of which a total of 83 are 
successes.  The number of successes on T3 at Centre 1 is generated similarly, as are the 
success counts for other centres.  These success counts are then used to generate the 
numbers of successes on the two treatments at the 10th interim analysis, and so on back to 
the first interim analysis.  In the reverse simulation, the numbers of patients and of 
successes on T4 at the 5
th interim analysis is taken to be as recorded in Table 5, and the 
numbers of successes at earlier interim analyses are filled in by hypergeometric simulation; 
for T2 the reverse simulation begins at the 4
th interim analysis. 
The next step is to determine which of the reverse simulated runs are consistent 
with the outcome of the trial, and to delete those which are not.  For each reverse 
simulated run, every remaining treatment comparison is considered at each interim analysis 
in turn.  The relevant stratified values of Z and V can be computed from the simulated 
success counts.  Consider the comparison between treatments Ti and Tj, i  j = 1, 2, 3, 4.  
First, consider an interim analysis which in the real trial is the last for both Ti and Tj.  In such 
a case the reverse simulated data for both treatments will be identical to those used in the 
actual trial, and the conclusions will be the same.  No runs will be deleted on the basis of 
these data. 
Now consider an interim analysis which in the real trial is the last for Ti, but after 
which Tj continued to be observed.  If, in the real trial Tj was found better than Ti at this 
interim analysis, then any reverse simulation for which this did not occur is deleted.  It is 
possible that in the real trial Tj was not found better than Ti at this interim analysis, Ti being 
eliminated in comparison with another treatment.  In this case, any reverse simulation in 
which Ti was found to be better than, or worse than, Tj is eliminated.  Furthermore, any 
reverse simulation run that ends at this interim analysis with the conclusion that there is no 
difference between any of the remaining treatments will be deleted. 
Finally, consider an interim analysis which in the real trial is not the last for either Ti 
or Tj.  Any reverse simulation for which Tj was found better than, or worse than, Ti at this 
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interim analysis is deleted.  Once more, any reverse simulation run that ends at this interim 
analysis with the conclusion that there is no difference between any of the remaining 
treatments will be deleted. 
For each of the reverse simulation runs that remains after the deletion process, the 
estimate 13 131 131
ˆ Z V  is found from (1) using the reverse simulated stratified test statistics 
for the comparison of T1 and T3 from the first interim analysis.  The mean of the values of 
13ˆ provides the RB2 estimate 13  and the corresponding variance provides  13ˆvar , S* n* .    
The latter is used in a suitably amended version of equation (2) to provide a value for 
 13se  .     
A second reverse simulation is then run, starting at the 5th interim analysis, and using 
the actual numbers of successes on T1, T3 and T4 at each centre at that analysis as the 
starting point for each reverse simulation.  Following the deletion of runs that would have 
been incomplete, 14  and 34  and their corresponding standard errors are found.  The third 
reverse simulation starts at the 4th interim analysis and uses the actual numbers of 
successes observed on all treatments at each centre at that analysis as the starting point for 
each reverse simulation.  This provides the estimates 12 , 23  and 24  and their 
corresponding standard errors.  
In the results that follow, one modification of the method implemented in the 
unstratified case is made.  For the purposes of computing the ij  and their standard errors 
only, Vijc1 is replaced by ijc1V , where 
 
 
  
   
ic1 jc1 ic1 jc1 ic1 jc1 ic1 jc1
ijc1 2
ic1 jc1 ic1 jc1
n n S S n n S S
V
n n n n 1
   
 
  
,                                                                   (7) 
 
and the additional subscript c indicates the centre, c = 1, ..., 4.  The usual expression for  
Vijc1, is used during the conduct of the trial and when assessing whether simulated trial runs 
are complete.  However, it is    ij1 ij11 ij21 ij31 ij41 ij11 ij21 ij31 ij41ˆ Z Z Z Z V V V V            that is 
averaged over complete simulated runs to provide ij  and used to determine  ijse  .  The 
reason for this change is pragmatic: without it estimates show excessive bias and standard 
errors are too small or sometimes non-existent as equation (2) involves the square root of a 
negative value.  Use of ijc1V  largely avoids these problem, as E(Zijc1) is closer to ijc1V  than it is 
to ijc1V  and var(Zijc1) is closer to ijc1V  than it is to ijc1V .  In the unstratified case the sample 
sizes per treatment at the first interim analysis are quite large, and so this level of attention 
to detail is unnecessary.  In the stratified case, it is the sample sizes within centre that 
determine the accuracy of the procedure, and without the use of (7) these are now too 
small to guarantee the accuracy of the estimates, or the existence of the standard errors. 
 Table 7 compares a naïve analysis in which pairs of treatments are compared 
using the data available at the last interim analysis in which both were present but ignoring 
the sequential nature of the trial, with the RB2 method described above.  The number of 
reverse simulations was set at 10 million.  It can be seen that the effect of allowance for the 
sequential design is to reduce the magnitude of the estimates of the advantage of T1 over 
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each of T2 and T4, while the estimate of the advantage of T1 over T3 is hardly changed.  The 
corresponding confidence intervals are all widened.  The other estimates of treatment 
effects have also been reduced in magnitude, but the effect on their standard errors is less 
marked.  The SAS programs leading to the RB2 analyses shown in Table 7 is provided as 
supplementary material of this paper. 
Table 8 shows the results from 1000 replicate simulations of a situation in which T1 is 
the best treatment.  To achieve a feasible computational time, one million reverse 
simulations are used in each analysis.  Furthermore, for ease of computation, Option 1 is 
chosen so that a single set of reverse simulations will yield estimates and confidence 
intervals for all treatment comparisons.  For comparison, the results from naïve analyses 
based on the test statistics Z and V comparing the final samples simulated from each 
treatment (that is using Option 1) are also shown. The comparisons of T1 with the three rival 
treatments each lead to overestimation of treatment effect when the naïve analysis is used, 
whereas the estimates drawn from RB2 show very little bias.  The results for the other 
comparisons are similar for the two approaches, with RB2 being a little less biased.  In most 
of the simulated realisations, the timing of these comparisons will have been determined by 
the completion of others, and so the effects of the sequential design would be expected to 
be less marked.  The coverage probabilities for confidence intervals based on the naïve 
approach are too low, while those for RB2 are satisfactory.  Other simulations were 
conducted in which each RB2 analysis depended on only 100,000 reverse simulations.  
These led to less accurate estimation and markedly conservative confidence intervals.  It 
appears that, provided that sufficient reverse simulations are used, RB2 leads to accurate 
analyses that overcome the potential bias inherent in the use of data-dependent elimination 
and stopping rules.   
 
 
 
6. Conclusions 
 
The approach presented here for estimation following a sequential trial is quite general, and 
can be implemented for a wide variety of designs.  In the case of a comparison of a single 
experimental treatment with a single control arm, the method works and provides 
satisfactory results, as has been demonstrated in Section 4 above.  However, there are 
already numerous methods of computing point and interval estimates in the two-treatment 
context.  In particular, methods based on orderings of the final sample space are just as 
good for computing point estimates and more accurate for finding confidence intervals than 
the approach introduced here. They are also less computationally demanding. 
 The utility of the approach described here is in more complicated designs comparing 
multiple treatments or with flexible adaptive features, as reverse simulation is based only 
on the form of the stopping rules implemented and not on their theoretical properties.  The 
method has been illustrated and evaluated for one particular form of comparison of four 
treatments which motivated its development, but its implementation is certainly not 
restricted to that design. 
 The claim for the unbiasedness of estimates produced using Method RB2 is 
underpinned by rigorous asymptotic theory, and the simulation results obtained for their 
accuracy in Section 5 are satisfactory.  The method for deriving confidence intervals is less 
secure as it depends on two unverified assumptions: that the expected conditional variance 
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of the unbiased estimate at the first interim analysis can be approximated by its observed 
value from reverse simulations, and that the adjusted estimate follows the normal 
distribution.  Simulations in Sections 4 and 5 demonstrate that the resulting intervals are 
conservative but serviceable.  It should be repeated that the number of reverse simulations 
needed to achieve satisfactory results is large.  Here, in single demonstration analyses, 10 
million replicates were used.  In earlier work, we found that using fewer replicates led to 
less satisfactory results. 
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Table 1: Properties of the four treatment design from million-fold simulations 
 
win1 = proportion of runs in which T1 wins 
elim4 = proportion of runs in which T4 is eliminated 
nod = proportion of runs in which:  for Cases 1-8 and Mixed Cases I –II, T1 and T2 are declared 
no different from one another; for Cases 9-12 and Mixed Case III, T1 , T2 and T3 are 
declared no different from one another;  for Cases 13-16 and Mixed Case IV, all 
treatments are declared no different from one another 
still = proportion of runs in which not all treatment comparisons are resolved after 2772 
responses 
 
Case p1 p2 p3 p4 E(n) win1 elim4 nod still 
1 0.500 0.400 0.400 0.400 1426 0.819 0.920 0.045 0.000 
2 0.600 0.500 0.500 0.500 1427 0.819 0.920 0.044 0.000 
3 0.692 0.600 0.600 0.600 1537 0.816 0.916 0.043 0.004 
4 0.771 0.692 0.692 0.692 1765 0.802 0.902 0.039 0.039 
Mixed Case I  (Cases 1-4) 1531 0.819 0.918 0.043 0.004 
5 0.500 0.500 0.400 0.400 1389 0.025 0.975 0.901 0.000 
6 0.600 0.600 0.500 0.500 1411 0.025 0.975 0.903 0.000 
7 0.692 0.692 0.600 0.600 1540 0.026 0.974 0.901 0.002 
8 0.771 0.771 0.692 0.692 1803 0.026 0.966 0.885 0.024 
Mixed Case II  (Cases 5-8) 1524 0.026 0.975 0.975 0.001 
9 0.500 0.500 0.500 0.400 1540 0.005 0.988 0.861 0.000 
10 0.600 0.600 0.600 0.500 1583 0.005 0.988 0.861 0.000 
11 0.692 0.692 0.692 0.600 1752 0.005 0.987 0.857 0.003 
12 0.771 0.771 0.771 0.692 2066 0.005 0.975 0.814 0.057 
Mixed Case III  (Cases 9-12) 1722 0.005 0.987 0.857 0.003 
13 0.500 0.500 0.500 0.500 1795 0.002 0.066 0.785 0.001 
14 0.600 0.600 0.600 0.600 1862 0.002 0.066 0.782 0.004 
15 0.692 0.692 0.692 0.692 2071 0.002 0.066 0.748 0.053 
16 0.771 0.771 0.771 0.771 2381 0.001 0.064 0.591 0.266 
Mixed Case IV  (Cases 13-16) 2028 0.002 0.066 0.760 0.036 
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Table 2: Details of 12 realisations of the triangular design and of two simple forms of analysis 
Terminal values of the number of interim analyses, total sample size, the numbers of successes on T1 and T2 and of the statistics Z and V are 
shown as int*, n*, S1*, S2*, Z* and V* respectively.  Patients are evenly divided between the two treatments so that n1* = n2* = ½n*.   
b* denotes the boundary crossed, with 0 denoting the lower boundary and 1 the upper boundary. 
For the naïve analysis, the estimated value of  is Z*/V* with 95% confidence interval (L, U) = ( ˆ   1.96/V*). 
The orderings analysis is based on the ordering of Fairbanks and Madsen [21] and computed following [19, 20]. 
 
Case Terminal data Naïve analysis  Orderings analysis 
int* n* S1* S2* Z* V* b* p-val ˆ  L U p-val M L U 
1   2 144   35   59 12.0   8.160 0 1.000 1.471 2.157 0.784 1.000 1.470 2.156 0.783 
2   3 216   68   87 9.5 10.943 0 0.998 0.868 1.461 0.276 0.997 0.857 1.454 0.256 
3   4 288 102 118 8.0 12.986 0 0.987 0.616 1.160 0.072 0.983 0.599 1.149 0.044 
4 10 720 284 285 0.5 29.833 0 0.537 0.017 0.376   0.342 0.485   0.007 0.358   0.378 
5   8 576 201 201     0.0 30.359 0 0.500   0.000 0.356   0.356 0.464   0.017 0.344   0.382 
6 13 936 275 259     8.0 57.337 0 0.144   0.140 0.119   0.398 0.089   0.187 0.084   0.468 
7   9 648 252 222   15.0 31.819 1 0.004   0.471   0.124   0.819 0.007   0.454   0.097   0.807 
8   6  432 120   88   16.0 26.963 1 0.001   0.593   0.216   0.971 0.003   0.563   0.168   0.949 
9   6 432 161 130   15.5 23.745 1 0.001   0.653   0.251   1.055 0.002   0.623   0.205   1.034 
10   5 360 135 108   13.5 19.744 1 0.001   0.684   0.243   1.125 0.002   0.676   0.231   1.120 
11   5 360 124   92   16.0 21.600 1 0.000   0.741   0.319   1.162 0.001   0.704   0.260   1.137 
12   3 216   82   55   13.5 12.527 1 0.000   1.078   0.524   1.631 0.000   1.075   0.519   1.629 
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Table 3: Analyses of the 12 realisations of the triangular design based on Rao-Blackwellisation 
 
Case Method RB1 Method RB2
   se L U % complete   se L U 
1 1.463  0.360  2.169 0.757 99.3 1.473 0.383 2.225 0.722 
2 0.823  0.325  1.461 0.185  89.3 0.834 0.334 1.488 0.180 
3 0.560  0.298  1.145   0.025  79.9 0.567 0.295 1.145   0.010 
4   0.046  0.204  0.354   0.447  55.7   0.046 0.158 0.263   0.356 
5   0.051  0.201  0.342   0.445 67.0   0.052 0.183 0.307   0.411 
6   0.224  0.166  0.101   0.549  17.0   0.227 0.158 0.081   0.536 
7   0.420  0.197    0.033   0.806  63.7   0.424 0.185   0.062   0.787 
8   0.519  0.214    0.100   0.939 56.0   0.529 0.213   0.110   0.947 
9   0.580  0.226    0.136   1.024  54.9   0.584 0.229   0.135   1.033 
10   0.653 0.239    0.184   1.122  85.7   0.658 0.245   0.179   1.138 
11   0.655  0.238   0.188   1.122 58.5   0.671 0.243   0.195   1.147 
12   1.059 0.291       0.490       1.629 95.8   1.069 0.312   0.457   1.680 
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Table 4: Evaluation of the naïve and the Rao-Blackwellisation methods based on 1,000-fold simulations  
 
 Naïve Method RB1 Method RB2 
True value of    0   0.246 0.405   0   0.246 0.405   0   0.246 0.405 
Estimate of  0.069   0.244 0.459 0.001   0.248 0.410 0.006   0.246 0.408 
Standard deviation   0.209   0.227 0.213   0.213   0.182 0.203   0.233   0.187 0.196 
Standard error   0.184   0.154 0.169   0.209   0.184 0.197   0.201   0.175 0.190 
L 0.430 0.058 0.128 0.408 0.113 0.025 0.399 0.096 0.034 
U   0.293   0.546 0.790    0.410   0.609 0.795   0.388   0.589 0.781 
Probability that
(L ,U) 
  0.943   0.932 0.920    0.976   0.976 0.972   0.958   0.967 0.971 
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Table 5: Raw data from a single simulation of the four treatment design 
 
Treatment Interim Centre n S Sample size at each interim Number of successes at each interim 
1 12 1 103   83 11, 18, 30, 41, 50, 57, 65, 76, 86, 92, 98, 103 10, 17, 27, 35, 41, 46, 53, 63, 69, 74, 78, 83 
  2 100   67 10, 16, 25, 33, 41, 49, 60, 71, 82, 88, 96, 100  10, 14, 20, 25, 30, 34, 40, 47, 58, 61, 65, 67  
  3 104   64 7, 17, 25, 35, 44, 55,  63, 68, 72, 83, 90, 104 6, 11, 16, 20, 26, 32,  36, 41, 43, 49, 55, 64 
  4 125   68 8, 21, 28, 35, 45, 55,  64, 73, 84, 97, 112, 125 4, 13, 15, 20, 27, 34,  38, 45, 48, 53, 62, 68 
  Total 432 282   
2   4 1   39   25 12, 24, 31, 39 9, 17, 19, 25 
  2   30   13 6, 13, 25, 30  4, 8, 12, 13  
  3   35   21 7, 16, 22, 35 5, 11, 15, 21 
  4   40   11 11, 19, 30, 40 1, 5, 8, 11 
  Total 144   70   
3 12 1 111   85 9, 19, 29, 39, 48, 57,  67, 74, 85, 91, 102, 111  8, 15, 21, 27, 33, 41,  49, 56, 65, 70, 79, 85  
  2   94   56 7, 15, 24, 32, 40, 49,  57, 64, 72, 79, 88, 94 5, 9, 15, 22, 28, 31,  33, 38, 44, 47, 52, 56 
  3 111   60 9, 17, 25, 32, 42, 50,  58, 68, 76, 90, 101, 111 3, 5, 8, 13, 21, 27,  31, 37, 41, 48, 55, 60 
  4 116   45 11, 21, 30, 41, 50, 60, 70, 82, 91, 100, 105, 116 4, 7, 12, 15, 18, 23, 26, 34, 37, 42, 44, 45 
  Total 432 246   
4   5 1   50   32 9, 15, 23, 36, 50 5, 11, 17, 24, 32 
  2   47   27 9, 20, 32, 42, 47 6, 11, 16, 24, 27 
  3   40   18 11, 19, 28, 32, 40 5, 8, 12, 14, 18 
  4   43   16 7, 18, 25, 34, 43 3, 9, 10, 13, 16 
  Total 180   93   
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Table 6: Comparative data derived from Table 5 
 
 
Comparison Interim Site Z V ˆ  Conclusion 
T1 vs T2   4 1   4.25   3.75   1.133 T1 knocks out 
T2 at 4
th 
interim 
  2   5.10   3.76   1.356 
  3 0.50   4.25 0.118 
  4   5.53   4.53   1.221 
  Total 14.38 16.28   0.883 
T1 vs T3 12 1   2.14   9.02   0.237 T1 knocks out 
T3 at 12
th 
interim 
  2   3.60 11.24   0.320 
  3   4.02 13.11   0.307 
  4   9.39 14.98   0.627 
  Total 19.15 48.35   0.396 
T1 vs T4   5 1   4.50   4.93   0.913 T1 knocks out 
T4 at 5
th 
interim 
  2   3.44   5.00   0.688 
  3   2.95   5.23   0.564 
  4   5.01   5.49   0.912 
  Total 15.91 20.64   0.771 
T2 vs T3   4 1 1.00   4.33 0.231 No 
conclusion   2 3.94   3.81 1.034 
  3   3.23   4.18   0.773 
  4 1.84   4.41 0.417 
  Total 3.54 16.73 0.212 
T2 vs T4   4 1 0.48   4.24 0.113 No 
conclusion   2 2.42   4.37 0.554 
  3   2.72   4.17   0.652 
  4 1.97   4.03 0.489 
  Total 2.15 16.81 0.128 
T3 vs T4   5 1   1.16   5.47   0.212 No 
conclusion   2   2.71   5.02   0.540 
  3   1.02   5.11   0.200 
  4 0.28   5.36 0.052 
  Total   4.62 20.97   0.220 
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Table 7:  Analyses of the data from the single simulated run of the sequential four treatment comparison shown in Tables 5 and 6   
In the naïve analyses, the sequential nature of the trial is ignored 
The Rao-Blackwellisation method, RB2, is based on 10 million replicate reverse simulations 
 
Comparison Naïve Proportion 
complete 
RB2 
ˆ  se L U   se L U 
T1 vs T2    0.883 0.248     0.347 1.319 0.7381     0.869 0.286    0.309    1.429 
T1 vs T3    0.396 0.144     0.114 0.678  0.0199     0.405 0.220  0.027    0.837  
T1 vs T4    0.771 0.220     0.340 1.202  0.3050     0.667 0.256    0.165    1.169  
T2 vs T3 0.212 0.244  0.690  0.266  0.7381 0.167 0.255  0.667  0.333  
T2 vs T4 0.128 0.244  0.606  0.350 0.7381 0.069 0.249  0.557     0.418 
T3 vs T4    0.220 0.218  0.207  0.647  0.3050     0.165 0.225 0.277     0.606  
 
 
Table 8: Evaluation of the naïve method and the Rao-Blackwellisation method RB2 in the four treatment case 
Both evaluations are based on 1,000-fold simulations and each RB2 analysis employed 1,000,000 reverse-simulations 
The RB2 results are based on the 893 replicates in which 1000 or more reverse simulations were complete.    
 
Method Naïve RB2 
Comparison T1 vs T2   T1 vs T3   T1 vs T4   T2 vs T3   T2 vs T4   T3 vs T4 T1 vs T2   T1 vs T3   T1 vs T4   T2 vs T3   T2 vs T4   T3 vs T4 
True value of  0.693   0.405 0.405 0.288 0.288   0.000 0.693   0.405   0.405 0.288 0.288   0.000 
Estimate of  0.771   0.462 0.461 0.302 0.304 0.002 0.690   0.405   0.395 0.291 0.301 0.010 
Standard deviation 0.217   0.183 0.185   0.208   0.213   0.178 0.242   0.202   0.204   0.225   0.226   0.182 
Standard error 0.193   0.160 0.160   0.196   0.196   0.165 0.252   0.219   0.219   0.213   0.213   0.185 
L 0.393   0.149 0.147 0.687 0.688 0.325 0.195 0.024 0.035 0.708 0.719 0.372 
U 1.149   0.775 0.773   0.083   0.081   0.322 1.184   0.833   0.824   0.126   0.117   0.352 
Probability 
that(L ,U) 
0.932   0.925 0.924   0.941   0.935   0.943 0.951   0.973   0.965   0.962   0.955   0.968 
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Figure 1:  The elimination and stopping rule for a single pair of treatments 
 
 
 
Figure 2:  Estimates and 95% confidence limits for  from the Rao-Blackwellisation 
approaches, the orderings analysis and the naïve approach - with the naïve estimate 
subtracted - plotted against the naïve estimate for Cases 1-12 
